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INTRODUCTION
Invasive fungal infections (IFI) are an increasing global health problem, resulting in significant morbidity and mortality among individuals with impaired immunity [1] [2] [3] . Despite recent advances in the care of patients with IFI, conventional therapeutic options when used alongside anti-fungal therapy as an adjunctive treatment leading to faster resolution of infection compared to antifungal therapy alone [25, 26] .
Granulocyte-macrophage colony stimulating factor (GM-CSF) is also licenced for treatment of chemotherapy-associated neutropenia. It promotes the production, maturation, activation, and migration of neutrophils, monocytes, macrophages and lymphocytes [27] , and has potential advantages over G-CSF due to its wider effects on the immune response [28] . Animal and cell culture models suggest GM-CSF is important in the host response against Aspergillus and Cryptococcus [29, 30] , and individuals with anti-GM-CSF auto-antibodies have been found to be at increased risk of infection with C. gattii [31] . In patients receiving chemotherapy for acute myeloid leukaemia and allogeneic haematological stem cell transplantation (HSCT), prophylactic GM-CSF results in faster neutrophil recovery, lower all-cause mortality, lower transplantation-related mortality, and lower invasive fungal disease-associated mortality [32] [33] [34] . Case reports and case series suggest GM-CSF may be beneficial when used alongside antifungal treatments in treating a variety of IFI, including candidiasis, aspergillosis, and zygomycosis [35] [36] [37] .
Macrophage colony-stimulating factor (M-CSF) also rapidly increases myeloid differentiation of hematopoietic stem cells via activation of the myeloid regulator PU.1 [38] . Data from animal models suggest that M-CSF may also play a role in controlling invasive fungal infections [39] . However, it has never been tested in humans and unlike G-CSF and GM-CSF, there is no pharmaceutical product available.
Interferon-gamma (IFN-γ) is produced by NK cells and T lymphocytes and promotes classical activation of macrophages resulting in increased phagocytosis, production of reactive oxygen species and reactive nitrogen intermediates; it is a vital component of the host immune response against intracellular pathogens [40] . IFN-γ knockout mice and people with impaired IFN-γ signalling (IFN-γ receptor 1 deficiency or anti-IFN-γ autoantibodies) are at significantly increased risk of severe infection with C. albicans, C. neoformans, H. capsulatum and Coccidioides immitis [41] [42] [43] [44] [45] [46] . In animal models of invasive aspergillosis, IFN-γ enhances neutrophil function augments the response to anti-fungal therapy resulting in significantly improved survival [47, 48] . Improvements in neutrophil function resulting in significant reductions in serious infections have also been observed in patients with chronic granulomatous disease (CGD) treated with prophylactic IFN-γ [49] .
In HIV-infected individuals with cryptococcal meningitis, low CSF concentrations of IFN-γ are associated with higher fungal burden, slower clearance of Cryptococcus, and increased mortality [50] . Animal models have demonstrated significantly improved survival when IFN-γ was used as an adjunctive treatment alongside amphotericin B [51] , prompting two phase II trials of adjunctive IFN-γ in AIDS patients with cryptococcal meningitis [52, 53] . The first showed a non-significant trend towards better CSF sterilization; the second showed significantly faster clearance of infection when IFN-γ was added to antifungal treatment. IFN-γ has also been used to augment the host immune response in cases of HIV-negative patients with cryptococcal meningitis, invasive aspergillosis, invasive candidiasis and disseminated H. capsulatum infection [54] [55] [56] .
LEUKOCYTE TRANSFUSIONS
Infusion of donor granulocytes is an experimental technique to improve survival from invasive fungal infections in the setting of profound neutropenia and requires harvesting of granulocytes from an ABO matched donor using leukophoresis. Case reports and retrospective case-control studies suggest granulocyte transfusions are feasible, safe and associated with better than expected survival rates [57] [58] [59] . However, clinical benefit has yet to be clearly demonstrated, and the single randomised controlled trial conducted to date showed no survival benefit in the setting of neutropenic sepsis [60] . In a mouse model of invasive aspergillosis, significant improvement in outcome was observed when granulocytes were loaded with the lipophilic triazole posaconazole [61] .
Adoptive transfer of pathogen-specific T cells is another promising treatment strategy. Prolonged lymphopenia is a major risk factor for post-engraftment invasive aspergillosis following HSCT, and the presence of Aspergillus-specific Th1 cells is associated with successful resolution of infection [62] [63] [64] . Murine studies have demonstrated that adoptive transfer of Aspergillus-specific Th1 memory CD4 T cells (generated through exposure to Aspergillus culture filtrate antigens) results in prolonged survival in experimentally infected mice [65] . This strategy was replicated in a single small human study involving ten HSCT patients with pulmonary aspergillosis; reductions in serum galactomannan and a trend towards improved survival were seen [66] .
To expedite clonal expansion, co-stimulatory molecules (CD137 and CD154) can be used to select antigen-specific T cells. This technique has been used to generate Aspergillus-specific T cells, with in vitro activity against a wide range of fungal isolates [67] . In a further refinement, adoptive transfer of chimeric antigen receptor (CAR) T cells targeting tumor antigens has been adapted to target fungal pathogens [68] . This involves fusing the extracellular domain of Dectin-1 to a CAR cassette and transferring into human T cells resulting in a modified β-1,3-glucan-specific T lymphocyte. Such cells have been shown to inhibit germinating Aspergillus spores in vitro, and improve outcome in experimentally infected mice [69] . These two techniques are clarified further in Figure 1 .
An alternative approach to improving T cell responses is the use of immune checkpoint inhibitors targeting the inhibitory T cell co-receptors, including programmed death 1 (PD-1) [70] . Although mostly studied in cancer, in a murine model of Candida blood stream infection, PD-1 blockade improved T cell responses and survival when combined with fluconazole [71] . A trial of PD-1 blockade was also used successfully in a patient with refractory mucormycosis in combination with IFN-γ and anti-fungal therapy [72] . a monoclonal antibody with pan-fungal efficacy have shown some promise with monoclonal antibodies directed again β-glucans [79] and β-1,6-poly-N-acetyl-D-glucosamine [80] .
VACCINATION
No fungal vaccine has been licensed for human use, and special challenges arise in developing vaccines for diseases that almost exclusively affect immune compromised individuals. While some live attenuated fungal strains induce protective immunity in mice [81] , caution needs to be exercised that such strains are sufficiently attenuated so as not to cause disease in persons with impaired immunity. Killed strains obviate this concern but autoimmune and inflammatory reactions to vaccine components need to be carefully monitored. For example, a formalin-killed Coccidioides spherule whole cell vaccine targeting individuals at risk for the endemic mycosis coccidioidomycosis showed a trend towards protection but was poorly tolerated [82] .
One strategy for fungal vaccines is utilization of conserved fungal cell wall components to stimulate adaptive immunity. This strategy has the potential for eliciting protective antibodies against multiple genera of fungi. While cell wall glycans are poorly immunogenic, glycan conjugate vaccines effectively induce adaptive responses [83] . A glycoconjugate vaccine consisting of brown algae β-glucan covalently linked to diphtheria toxin protects against challenge with multiple fungi in animal models [84] , and similar approaches have been used to develop protective antibodies against capsular components of C. neoformans [85] .
Due to their capacity to be innately recognized by the host immune system, fungal cell wall glycans (β-glucans, mannans and chitiosan) have been utilized as antigen delivery systems and adjuvants [83] . The benefits of this technique have been demonstrated in murine experiments where encapsulation of antigen in β-glucan particles resulted in durable antigen-specific Th1 and Th17 T-cell and antibody responses [86, 87] . Dendritic cell (DC) vaccination is another potentially beneficial approach and in murine models of HSCT associated aspergillosis, this resulted in improved antigen-specific Th1 responses, accelerated lymphoid and myeloid cell recovery, and improved survival following infective challenge [88] .
An active area of investigation is the identification of immunoreactive fungal antigens that can be used in subunit vaccines. Although many antigens are species-or genus-specific and would elicit protective responses against only a narrow range of fungal pathogens, this approach may have merit in targeted at-risk populations. For example, a vaccine consisting of a recombinant N-terminus of Als3 protein (required by Candida for endothelial adherence) has been shown to induce antigen-specific antibody, Th1 and Th17 T-lymphocyte responses, and reduce fungal burden in hematogenously challenged mice [89] .
Phase I trials have shown it to be safe and immunogenic in healthy adults [90] , and a clinical trial of this vaccine in women with recurrent vulvovaginal candidiasis recently completed enrolment [91] . Scriven 
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IMMUNE SUPPRESSIVE THERAPY
Finally, although the majority of evidence for immune modulation in IFI favours techniques that stimulate the immune response, in some fungal infections inhibition of an overly exuberant response may be preferential. In patients with HIV-associated Pneumocystis jirovecii pneumonia (PCP), adjunctive corticosteroids reduce IL-8 driven neutrophil pulmonary infiltration and decrease patient mortality in severe disease [92, 93] . Corticosteroids may also reduce the incidence of cerebrovascular events in Coccidioides immitis meningitis [94] and beneficial effects have been reported in individual patients with chronic disseminated (hepatosplenic) candidiasis and in cryptococcal meningitis-IRIS [7, 17] . However, the use of corticosteroids in patients with HIV-associated cryptococcal meningitis who do not have IRIS is not recommended after a clinical trial demonstrated slower clearance of infection and worse clinical outcome [95] . This is consistent with immunological studies that demonstrate an association between a poor inflammatory response in the CSF and blood, and increased disease severity and mortality [96, 97] .
FUTURE DIRECTIONS
The pathogenesis of fungal infections is instrinsically linked to host immune response. Given the recent advances in immune therapy against cancer, the prospect of modulating the host immune response in fungal infections is appealing but thus far elusive. Many techniques have shown great promise in vitro and in animal models but very few have been tested, much less proven to work, in patients. Future research should concentrate on translating promising ideas such as adoptive T cell transfer and adjunctive IFN-γ therapy to the clinic and developing immune assays to identify groups of patients likely to benefit.
